Página principal > Resultados de la búsqueda: Egyed, Miklos
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
10 p, 345.6 KB Momelotinib long-term safety and survival in myelofibrosis : integrated analysis of phase 3 randomized controlled trials / Verstovsek, Srdan (The University of Texas, USA) ; Mesa, Ruben (UT Health San Antonio Cancer Center, San Antonio, USA) ; Gupta, Vikas (Princess Margaret Cancer Centre, Toronto, Canada) ; Lavie, David (Hadassah-Hebrew University Medical Center, Jerusalem, Israel) ; Dubruille, Viviane (Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Nantes, France) ; Cambier, Nathalie (Centre hospitalier r ' egional universitaire de Lille (CHRU Lille), Lille, France) ; Platzbecker, Uwe (University of Leipzig, Germany) ; Hus, Marek (Uniwersytet Medyczny w Lublinie, Lublin, Poland) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Oh, Stephen T. (Washington University School of Medicine, St. Louis, USA) ; Kiladjian, Jean Jacques (Universite de Paris, France) ; Vannucchi, Alessandro M. (University of Florence, Careggi University Hospital, Florence, Italy) ; Gerds, Aaron (Cleveland Clinic, USA) ; Egyed, Miklos (Teaching Hospital Mor Kaposi, Kaposv ' ar, Hungary) ; Mayer, Jiří (Masaryk University, Brno, Czech Republic) ; Sacha, Tomasz (Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland) ; Kawashima, Jun (Sierra Oncology, San Mateo, CA) ; Morris, Marc (Sierra Oncology, San Mateo, CA) ; Huang, Mei (Sierra Oncology, San Mateo, CA) ; Harrison, Claire (National Health Services (NHS) Foundation Trust, London, United Kingdom)
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). [...]
2023 - 10.1182/bloodadvances.2022009311
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3582-3591  
Registro completo - Creative Commons
2.
15 p, 1024.0 KB The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study / Zijlstra, Josée M. (Amsterdam UMC) ; Follows, George (Cambridge University Hospitals NHS Foundation Trust (Regne Unit)) ; Casasnovas, Rene-Olivier (University Hospital F. Mitterrand) ; Vermaat, Joost S. P. (Leiden University Medical Center) ; Kalakonda, Nagesh (University of Liverpool) ; Choquet, Sylvain (Hôpital Pitié Salpêtrière) ; Hill, Brian (Taussig Cancer Institute) ; Thieblemont, Catherine (Saint-Louis Hospital) ; Cavallo, Federica (University of Torino/AOU) ; la Cruz, Fatima De (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Kuruvilla, John (Princess Margaret Cancer Centre) ; Hamad, Nada (University of Notre Dame Australia) ; Jaeger, Ulrich (Medical University of Vienna) ; Caimi, Paolo (Case Western Reserve University) ; Gurion, Ronit (Rabin Medical Center) ; Warzocha, Krzysztof (Instytut Hematologii I Transfuzjologii) ; Bakhshi, Sameer (All India Institute of Medical Sciences (Nova Delhi, Índia)) ; Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Schuster, Michael (Stony Brook University Hospital) ; Egyed, Miklos (Teaching Hospital Mór Kaposi) ; Offner, Fritz (Ghent University Hospital (Bèlgica)) ; Vassilakopoulos, Theodoros P. (National and Kapodistrian University of Athens) ; Samal, Priyanka (Institute of Medical Sciences & SUM Hospital) ; Ku, Matthew (St Vincent's Hospital (Sydney)) ; Xu, Jenny (Karyopharm Therapeutics) ; Corona, Kelly (Karyopharm Therapeutics) ; Chamoun, Kamal (Karyopharm Therapeutics) ; Shah, Jatin (Karyopharm Therapeutics) ; Canales, Miguel (Hospital Universitario La Paz (Madrid)) ; Maerevoet, Marie (Institut Jules Bordet) ; Universitat Autònoma de Barcelona
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. [...]
2022 - 10.3390/cancers14030791
Cancers, Vol. 14 (february 2022)  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Egyed, M.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos